HER 2 Negative Breast Cancer | sciencenewsnet.in

Breaking News

New study shows how salmonella tricks gut defenses to cause infection

How ecDNA Fuels Cancer by Breaking the Laws of Biology

Creating a spatial map of the sea

Much Ado About Vacuum

Researchers Uncover Achilles Heel of Antibiotic-Resistant Bacteria

HSS Appoints Daphne A. Scott, MD, Chief of Primary Sports Medicine

Study: Coronary Function Testing Improves Diagnosis of Heart Disease in Women

Multi-disciplinary teams respond to recent hurricanes to measure real time impacts of storm surge, waves

New pathways for Alzheimer’s prevention

New research sheds light on a surprising connection between COVID-19 and cancer regression

16 Nov, 2024

Grantees Awarded as Part of the Breast Cancer Research Project Between NCCN and Lilly Oncology

December 3, 2020 sarah JonasAnnouncement

The NCCN Oncology Research Program (ORP) today announced five projects selected to receive funding for clinical and preclinical evaluation of abemaciclib, a cyclin dependent kinase (CDK) 4 & 6 inhibitor used in the treatment of HR+ and HER2- breast cancer.